Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

The CEO and Chief Commercial Officer provided updates on the manufacturing and distribution timeline for Myle, emphasizing on-time progress and no reimbursement hurdles. They discussed expectations for Q4 2024 sales and plans for European expansion, prioritizing regulatory submissions.